Ovid Therapeutics (OVID) Operating Leases (2022 - 2026)

Ovid Therapeutics has reported Operating Leases for 5 years, with the latest figure at $11.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 11.16% year-over-year to $11.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 11.16% YoY), and the FY2025 full-year result was $12.0 million, down 10.68% from the prior year.
• Operating Leases for Q1 2026 stood at $11.6 million, down from $12.0 million in the prior quarter.
• The five-year high for Operating Leases was $16.2 million in Q3 2022, with the low at $11.6 million in Q1 2026.
• Historically, Operating Leases has averaged $14.3 million across 5 years, with a median of $14.4 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases dropped 1.09% — and 2026, when it retreated 11.16%.
• Ovid Therapeutics' Operating Leases stood at $16.0 million in 2022, then declined by 7.78% to $14.8 million in 2023, then decreased by 9.06% to $13.4 million in 2024, then dropped by 10.68% to $12.0 million in 2025, then slipped by 3.13% to $11.6 million in 2026.
• The last three Operating Leases figures came in at $11.6 million (Q1 2026), $12.0 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.